{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T22:21:32Z","timestamp":1649110892040},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"s52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p id=\"P1_w2aab3b7c16b1b6b1aab1c16b1Aa\">Patients with long-standing type 2 diabetes mellitus (T2DM) can be clinically challenging for physicians to treat because these patients often lack sufficient \u03b2-cell function to respond to some oral glucose-lowering agents, may have profound comorbidities, and may have renal impairment that limits the use of traditional agents. These complications, in addition to older age, also increase the risk of hypoglycemia, which can be a major barrier to treatment success. Individualizing treatment targets to balance the benefits of glycemic control with risks of hypoglycemia is the first step to successfully treating these patients. Careful selection of combination therapy strategies to address limited \u03b2-cell function, renal function, and cardiovascular status, along with attention to selection of agents associated with lower risk of hypoglycemia, is important. Basal insulin analogs are often used in patients with long-standing diabetes to address insulinopenic states. Incretin-based therapies, particularly GLP-1 receptor agonists, provide postprandial control with lower risks of hypoglycemia than prandial insulin. The author discusses the management of patients with long-standing diabetes who may have limited \u03b2-cell function and require transition to insulin therapy with gradual intensification.<\/jats:p>","DOI":"10.7556\/jaoa.2014.086","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T16:30:45Z","timestamp":1398270645000},"page":"22-29","source":"Crossref","is-referenced-by-count":2,"title":["Treating Patients With Diabetes of Long Duration: GLP-1 Receptor Agonists and Insulin in Combination"],"prefix":"10.1515","volume":"114","author":[{"given":"Etie S.","family":"Moghissi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"issue":"suppl 2","key":"2021042020280637573_j_jaoa.2014.086_ref_001_w2aab3b7c16b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S2.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan","volume":"17","author":"Handelsman","year":"2011","journal-title":"Endocr Pract."},{"issue":"6","key":"2021042020280637573_j_jaoa.2014.086_ref_002_w2aab3b7c16b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_003_w2aab3b7c16b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","article-title":"AACE Comprehensive Diabetes Management Algorithm 2013","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract."},{"issue":"4","key":"2021042020280637573_j_jaoa.2014.086_ref_004_w2aab3b7c16b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MLR.0b013e3181ca4035","article-title":"Clinical complexity in middle-aged and older adults with diabetes: the Health and Retirement Study","volume":"48","author":"Blaum","year":"2010","journal-title":"Med Care"},{"issue":"8","key":"2021042020280637573_j_jaoa.2014.086_ref_005_w2aab3b7c16b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","first-page":"554","DOI":"10.7326\/0003-4819-154-8-201104190-00007","article-title":"Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials","volume":"154","author":"Ismail-Beigi","year":"2011","journal-title":"Ann Intern Med."},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_006_w2aab3b7c16b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13300-013-0039-6","article-title":"Management of type 2 diabetes mellitus in older patients: current and emerging treatment options","volume":"4","author":"Moghissi","year":"2013","journal-title":"Diabetes Ther."},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_007_w2aab3b7c16b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jamainternmed.2013.12956","article-title":"Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study","volume":"174","author":"Huang","year":"2014","journal-title":"JAMA Intern Med."},{"issue":"suppl 2","key":"2021042020280637573_j_jaoa.2014.086_ref_008_w2aab3b7c16b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1046\/j.1463-1326.1999.0010s2007.x","article-title":"The natural history of diabetes-related complications: the UKPDS experience\u2014United Kingdom Prospective Diabetes Study","volume":"1","author":"Matthews","year":"1999","journal-title":"Diabetes Obes Metab."},{"issue":"21","key":"2021042020280637573_j_jaoa.2014.086_ref_009_w2aab3b7c16b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)\u2014UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"issue":"suppl 1","key":"2021042020280637573_j_jaoa.2014.086_ref_010_w2aab3b7c16b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S1751-9918(10)60008-3","article-title":"Practical guidance to insulin management","volume":"4","author":"Meneghini","year":"2010","journal-title":"Prim Care Diabetes"},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_011_w2aab3b7c16b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract."},{"issue":"10","key":"2021042020280637573_j_jaoa.2014.086_ref_012_w2aab3b7c16b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","article-title":"Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"2021042020280637573_j_jaoa.2014.086_ref_013_w2aab3b7c16b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1177\/193229681300700524","article-title":"A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial","volume":"7","author":"Liebl","year":"2013","journal-title":"J Diabetes Sci Technol."},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_014_w2aab3b7c16b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"2021042020280637573_j_jaoa.2014.086_ref_015_w2aab3b7c16b1b6b1ab2b1c15Aa","volume-title":"New insulin glargine formulation: glucose control and hypoglycemia in people with type 2 diabetes using basal and mealtime insulin (EDITION I) [abstract 43LB]","author":"Riddle"},{"issue":"6","key":"2021042020280637573_j_jaoa.2014.086_ref_016_w2aab3b7c16b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1463-1326.2009.01060.x","article-title":"Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"2021042020280637573_j_jaoa.2014.086_ref_017_w2aab3b7c16b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1463-1326.2007.00804.x","article-title":"The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes\u2014results of the randomized, controlled PREDICTIVE 303 study","volume":"9","author":"Meneghini","year":"2007","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"2021042020280637573_j_jaoa.2014.086_ref_018_w2aab3b7c16b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1185\/03007990902840871","article-title":"Once-daily insulin detemir in a cohort of insulin-naive patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study","volume":"25","author":"Meneghini","year":"2009","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"2021042020280637573_j_jaoa.2014.086_ref_019_w2aab3b7c16b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"2021042020280637573_j_jaoa.2014.086_ref_020_w2aab3b7c16b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"2021042020280637573_j_jaoa.2014.086_ref_021_w2aab3b7c16b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1463-1326.2008.00873.x","article-title":"Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial","volume":"10","author":"Davies","year":"2008","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"2021042020280637573_j_jaoa.2014.086_ref_022_w2aab3b7c16b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"2021042020280637573_j_jaoa.2014.086_ref_023_w2aab3b7c16b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"issue":"9131","key":"2021042020280637573_j_jaoa.2014.086_ref_024_w2aab3b7c16b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)\u2014UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"2021042020280637573_j_jaoa.2014.086_ref_025_w2aab3b7c16b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3111\/13696998.2011.610852","article-title":"Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs","volume":"14","author":"Fidler","year":"2011","journal-title":"J Med Econ."},{"issue":"6","key":"2021042020280637573_j_jaoa.2014.086_ref_026_w2aab3b7c16b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jdiacomp.2005.08.010","article-title":"Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73","volume":"20","author":"Wright","year":"2006","journal-title":"J Diabetes Complications"},{"key":"2021042020280637573_j_jaoa.2014.086_ref_027_w2aab3b7c16b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/VHRM.S33934","article-title":"Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes","volume":"9","author":"Ahr\u00e9n","year":"2013","journal-title":"Vasc Health Risk Manag."},{"issue":"suppl 2","key":"2021042020280637573_j_jaoa.2014.086_ref_028_w2aab3b7c16b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.2337\/dcS13-2011","article-title":"Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes","volume":"36","author":"Defronzo","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"2021042020280637573_j_jaoa.2014.086_ref_029_w2aab3b7c16b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones [review]","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"issue":"3","key":"2021042020280637573_j_jaoa.2014.086_ref_030_w2aab3b7c16b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"2021042020280637573_j_jaoa.2014.086_ref_031_w2aab3b7c16b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/dom.12025","article-title":"Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature","volume":"15","author":"Balena","year":"2013","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"2021042020280637573_j_jaoa.2014.086_ref_032_w2aab3b7c16b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2337\/dc12-2718","article-title":"Effects of adding linagliptin to basal insulin tegimen for inadequately controlled type 2 diabetes: a >=52-week randomized, double-blind study","volume":"36","author":"Yki-Jarvinen","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_033_w2aab3b7c16b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsboll","year":"2010","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"2021042020280637573_j_jaoa.2014.086_ref_034_w2aab3b7c16b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin."},{"issue":"12","key":"2021042020280637573_j_jaoa.2014.086_ref_035_w2aab3b7c16b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","article-title":"Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycaemia","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_036_w2aab3b7c16b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med."},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_037_w2aab3b7c16b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/187221412800604563","article-title":"The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus","volume":"6","author":"Baruah","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov."},{"issue":"14","key":"2021042020280637573_j_jaoa.2014.086_ref_038_w2aab3b7c16b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"issue":"14","key":"2021042020280637573_j_jaoa.2014.086_ref_039_w2aab3b7c16b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med."},{"issue":"9","key":"2021042020280637573_j_jaoa.2014.086_ref_040_w2aab3b7c16b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1464-5491.2008.02484.x","article-title":"Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes","volume":"25","author":"Courreges","year":"2008","journal-title":"Diabet Med."},{"issue":"3","key":"2021042020280637573_j_jaoa.2014.086_ref_041_w2aab3b7c16b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1479164111408937","article-title":"Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies","volume":"8","author":"Marso","year":"2011","journal-title":"Diab Vasc Dis Res."},{"issue":"2","key":"2021042020280637573_j_jaoa.2014.086_ref_042_w2aab3b7c16b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4158\/EP11169.OR","article-title":"Clinical use of liraglutide in type 2 diabetes, and its effects on cardiovascular risk factors","volume":"18","author":"Varanasi","year":"2012","journal-title":"Endocr Pract."},{"issue":"1","key":"2021042020280637573_j_jaoa.2014.086_ref_043_w2aab3b7c16b1b6b1ab2b1c43Aa","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"2021042020280637573_j_jaoa.2014.086_ref_044_w2aab3b7c16b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-10-22","article-title":"Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes","volume":"10","author":"Ratner","year":"2011","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"2021042020280637573_j_jaoa.2014.086_ref_045_w2aab3b7c16b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","first-page":"pii: e001076","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstrom","year":"2012","journal-title":"BMJ Open"},{"issue":"1 suppl","key":"2021042020280637573_j_jaoa.2014.086_ref_046_w2aab3b7c16b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.amjmed.2010.11.005","article-title":"Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca","volume":"124","author":"Fonseca","year":"2011","journal-title":"Am J Med."}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.086\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.086\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T10:06:34Z","timestamp":1619172394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.086\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":46,"journal-issue":{"issue":"s52","published-online":{"date-parts":[[2014,5,1]]},"published-print":{"date-parts":[[2014,5,1]]}},"alternative-id":["10.7556\/jaoa.2014.086"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2014.086","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}